AAREYDRUGS · Aarey Drugs & Pharmaceuticals Ltd · Biotechnology & Drugs
AAREYDRUGS · Aarey Drugs & Pharmaceuticals Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
4.7% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 51 days old
Revenue (latest Q)
₹45 Cr
Revenue YoY
PAT YoY
-25.6%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1.9
P/S (TTM)
0.8
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| AAREYDRUGS (this stock) | 70.9 | 1.9 | +0.9% | +2.4% | 0.33 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
rising 1q
FII
falling 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-10-07 | AAREYDRUGS | 181007 | 1 | WEAK | BULK |
| 2026-09-30 | AAREYDRUGS | 144423 | 1 | STRONG | BULK |
| 2026-08-28 | AAREYDRUGS | 274415 | 1 | STRONG | BULK |
| 2026-08-26 | AAREYDRUGS | 154471 | 1 | STRONG | BULK |
| 2026-08-04 | AAREYDRUGS | 200000 | 1 | MEDIUM | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedAarey Drugs & Pharmaceuticals Limited's annual report for FY2025-26 outlines the company's operational and financial performance, including its manufacturing activities in intermediates and active pharmaceutical ingredients (APIs). The report mentions the company's plans to increase production capacity based on demand and to pursue backward and forward integration for products like DMA-HCL and Ortho chloro benzoic acid. The directors did not recommend a dividend for the year. The report also highlights compliance with corporate governance standards and internal control systems, as well as the company's adherence to legal and regulatory requirements.
- The company is manufacturing intermediates and APIs, with plans to increase capacity based on demand and pursue backward and forward integration.
- The directors did not recommend a dividend for the year ended March 31, 2026.
- The company has implemented internal financial control systems and adhered to corporate governance standards.
Key takeaway: Aarey Drugs & Pharmaceuticals Limited is focused on expanding its production capacity and integrating its product lines to meet demand, while maintaining compliance with corporate governance and internal control standards.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (5 items); Regulatory Action (4 items); Default / Covenant Breach (6 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
5 occurrencesRecent (last 12 months)
The auditor noted that the Company's tax litigations have outcomes that are material but not practicable to estimate, and the Company has been unable to reliably estimate the exposure.
Earlier (1-3 years ago)
The auditor notes that the company's statutory liabilities include pending tax litigations with outcomes that are material but not practicable to estimate cash outflow timings.
The auditor notes that the company's statutory liabilities include pending tax litigations with outcomes that are material but not practicable to estimate cash outflow timings.
The auditor noted the absence of significant periodic balance confirmation for debtors and creditors, relying on management representations, and highlighted uncertainty regarding the outcomes of pending tax litigations.
The auditor highlighted two emphasis of matter sections in the financial statements: (1) Plant and Machinery added to fixed assets are not yet usable, so depreciation hasn't been charged, and (2) closing balances of debtors and creditors are based on books without confirmations, which are subject to confirmation.
Regulatory Action
4 occurrencesRecent (last 12 months)
The company has not disclosed the allotment of 50,00,000 warrants in the shareholding pattern filed with the stock exchange for various quarters during FY 2025-26.
Earlier (1-3 years ago)
The company did not follow SEBI guidelines for preferential share issuance and failed to file related party transaction disclosures correctly, leading to a penalty of Rs. 188,800 from BSE.
Older (3+ years ago)
The company was levied a penalty by BSE Limited for not having six directors till July 1, 2020, as required under Regulation 17(1) of Listing Regulations, and has since paid the penalty.
The company has not disclosed requirements for allotment of equity shares under preferential issue as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09th September, 2015. The company delayed submission of disclosures under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. An independent director and his relative hold securities exceeding permissible limits under Regulation 16 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The company granted interest-free, unsecured loans to directors, companies, and others, violating Sections 185 and 186 of the Companies Act, 2013.
Default / Covenant Breach
6 occurrencesEarlier (1-3 years ago)
The company has unpaid income tax dues of 57,51,300/- for the assessment year 2024-25, with a due date of 15/01/2025, and unpaid TDS interest and late fees of 6,15,080/- from prior years, as well as an outstanding demand of 13,256/- under section 271(1)(c) of the Income Tax Act, 1961.
The company has unpaid income tax dues of 57,51,300/- for the assessment year 2024-25, with a due date of 15/01/2025, and unpaid TDS interest and late fees of 6,15,080/- from prior years, as well as an outstanding demand of 13,256/- under section 271(1)(c) of the Income Tax Act, 1961.
The company has outstanding income tax demands under sections 271(1)(c) and 143(1)(a) for the years 2000-01 to 2001-02, with amounts unpaid as of March 31, 2024.
The company has not complied with the provisions of Section 185 and 186 of the Companies Act regarding the grant of loans, investments, and guarantees.
Older (3+ years ago)
The company had outstanding income tax demand under section 143(1) as of March 31, 2022, with a payment date not specified.
The company has not scheduled repayment of principal and interest for a loan, and the amount is not overdue for more than 90 days as it is repayable on demand.
Routine disclosures
Contingent Liability
6 occurrencesRecent (last 12 months)
The company has pending tax litigations for various years, including demands under Income Tax Act and GST, with amounts ranging from 70,000 to 7,70,00,47, and appeals not yet filed.
Earlier (1-3 years ago)
The company has pending tax litigations under Income Tax and GST Acts, with specific contingent liabilities including an outstanding demand of 30,67,224/- under Income Tax Act AY 2008-09 and 8,62,09,504/- under GST Act FY 2017-18, with outcomes deemed material but not estimable.
The company has pending tax litigations under Income Tax and GST Acts, with specific contingent liabilities including an outstanding demand of 30,67,224/- under Income Tax Act AY 2008-09 and 8,62,09,504/- under GST Act FY 2017-18, with outcomes deemed material but not estimable.
The Company has various tax litigations pending before various authorities, the outcome of which are material but not practicable for the Company to estimate the timings of cash outflows.
The Company has various tax litigations pending before various authorities, the outcome of which are material but not practicable for the Company to estimate the timings of cash outflows.
Older (3+ years ago)
The company has pending tax litigations with a total contingent liability of Rs. 16,11,15,379 as of 31st March 2022.
Related-Party Transaction
7 occurrencesRecent (last 12 months)
The company has disclosed related-party transactions with directors, KMP, and their relatives, including loans and office rent, with specific amounts and parties involved.
Earlier (1-3 years ago)
The company has made loans and advances to Mihir Ghatalia, a managing director, and Nimit Impex Pvt Ltd, a company in which a director has an interest, with details of loan amounts, repayments, and interest.
The company has a related-party transaction involving a relative of the Managing Director with an amount of 5,322,720.00.
The company has not filed the disclosure of Related Party Transaction under Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
An Independent Director and his relative hold securities of the company in excess of permissible limits under SEBI regulations. The company has given a loan to the Independent Director, leading to board committee compositions not in compliance with SEBI regulations and the Companies Act, 2013.
Older (3+ years ago)
The company has disclosed entities in which directors or KMPs have interests, including Enam Organics India Ltd, Worth Investment & Trading Co Ltd, Aaradhana Energy Private Limited, and Mihir R Ghatalia (HUF). These are related-party transactions as per Ind AS 24 disclosures.
A relative of the Promoter transacted in the Company's securities twice, triggering SEBI regulations, but the transactions were not disclosed.
Statutory dues in dispute
1 occurrenceRecent (last 12 months)
The company has unpaid income tax dues amounting to various amounts under the Income Tax Act, 1961, with some disputes pending, as of March 31, 2026.